Phase II Trial of Opaganib Addition in Metastatic Castration‐Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide

Documenti analoghi

• Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201 : Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration‐Resistant Prostate Cancer
  di: Nadine Norton, et al.
  Pubblicazione: (2025)
• Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
  di: András Horváth, et al.
  Pubblicazione: (2025)
• Real‐World Outcomes of Combination Therapy With Radium‐223 and Enzalutamide Compared With Enzalutamide Alone in Patients With Metastatic Castration‐Resistant Prostate Cancer
  di: Kenichi Hata, et al.
  Pubblicazione: (2026)
• Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer
  di: Mark Hadigol, et al.
  Pubblicazione: (2025)
• Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
  di: Mitsuhisa Nishimoto, et al.
  Pubblicazione: (2025)